Beam Therapeutics (BEAM) Other financing activities (2019 - 2026)

Beam Therapeutics (BEAM) has reported Other financing activities for 8 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities rose 181.64% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $6.1 million (up 735.11% YoY), while the FY2025 annual figure was $4.8 million, changed N/A from the prior year.
• Other financing activities advanced to $2.0 million in Q1 2026 per BEAM's latest filing, from $1.9 million in the prior quarter.
• Across five years, Other financing activities topped out at $30.6 million in Q4 2023 and bottomed at -$2.2 million in Q4 2024.
• Historically, Other financing activities has averaged $2.6 million across 5 years, with a median of $1.1 million in 2022.
• On a YoY basis, Other financing activities climbed as much as 2661.34% in 2023 and fell as far as 3218.52% in 2023.
• Beam Therapeutics' Other financing activities stood at $1.1 million in 2022, then surged by 2661.34% to $30.6 million in 2023, then tumbled by 107.05% to -$2.2 million in 2024, then surged by 187.52% to $1.9 million in 2025, then gained by 7.37% to $2.0 million in 2026.
• Business Quant data shows BEAM's Other financing activities at $2.0 million in Q1 2026, $1.9 million in Q4 2025, and $412000.0 in Q3 2025.